Biotech News

Ascendis Pharma Reports Third Quarter 2026 Financial Results

Ascendis Pharma (ASND)Ascendis PharmaEarnings

Q3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for YORVIPATH ®, €59 million for SKYTROFA ®, and €16 million for YUVIWEL ® Received positive CHMP and COMP opinions recommending EU marketing authorization and maintenance of orphan medicinal product designation for

Related news

Ascendis Pharma

TransCon Technology Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology. Commercial Endocrinology Portfolio YORVIPATH is a parathyroid-hormone replacement therapy for chronic...

Recent company news

Stock data

Close
255.96 USD
Market cap
13.38B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States